Human TRAILR4/TNFRSF10D Antibody Summary
Ala56-His211
Accession # Q9UBN6
Applications
Human TRAIL R4/TNFRSF10D Sandwich Immunoassay
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
TRAIL R4/TNFRSF10D Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human TRAIL R4/TNFRSF10D Antibody. In the presence of the metabolic inhibitor actinomycin D, Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (Catalog # 633-TR) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TEC) induced cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line). Under these conditions, inhibition of Recombinant Human TRAIL/TNFSF10 (20 ng/mL) activity elicited by Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (90 ng/mL) is neutralized (green line) by increasing concentrations of Human TRAIL R4/TNFRSF10D Monoclonal Antibody (Catalog # MAB633). The ND50 is typically 0.3-1.8 µg/mL.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: TRAILR4/TNFRSF10D
Human TRAIL R4, also called decoy receptor 2 (DcR2) and TRUNND (TRAIL receptor with a truncated death domain), is a type I, TNF R family transmembrane protein, which is a receptor for TRAIL (APO2 ligand). In the TNF superfamily nomenclature, TRAIL R4 is designated as TNFRSF10D. TRAIL R4 is unique among the TRAIL receptors in that its cytoplasmic domain contains a truncated consensus death domain motif. Binding of TRAIL R4 does not result in an apoptotic signal. Overexpression of TRAIL R4 can protect cells bearing TRAIL R1 and/or TRAIL R2 from TRAIL-mediated apoptosis. The human soluble TRAIL R4/Fc chimera neutralizes the ability of TRAIL to induce apoptosis.
- Griffith, T.S. et al. (1998) Curr. Opin. Immunol. 10:559.
- Pan, G. et al. (1998) FEBS lett 424:41.
- Marsters, S.A. et al. (1997) Cur. Biol. 7:1003.
- Degli-Esposti, M.A. et al. (1997) Immunity 7:813.
Product Datasheets
Citations for Human TRAILR4/TNFRSF10D Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
14
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps
Authors: L Danish, D Imig, F Allgöwer, P Scheurich, N Pollak
PLoS ONE, 2018-06-21;13(6):e0198203.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes.
Authors: Neumann S, Hasenauer J, Pollak N, Scheurich P
J Biol Chem, 2014-04-24;289(23):16576-87.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells.
Authors: Tang X, Lu J, Tu H, Huang K, Fu R, Cao G, Huang M, Cheng L, Dai L, Zhang L
Anticancer Res, 2014-02-01;34(2):729-34.
Species: Rat
Sample Types: Whole Cells
Applications: Flow Cytometry -
TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells.
Cancer Gene Ther., 2012-07-06;19(9):652-8.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL).
Authors: Zauli G, Rimondi E, Celeghini C, Milani D, Secchiero P
J. Cell. Physiol., 2010-02-01;222(2):357-64.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients.
Authors: Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Mullauer L, Quendler H, Kohrgruber N, Stingl G
Blood, 2009-08-18;114(18):3854-63.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells.
Authors: Secchiero P, Melloni E, Corallini F, Beltrami AP, Alviano F, Milani D, D'Aurizio F, di Iasio MG, Cesselli D, Bagnara GP, Zauli G
Stem Cells, 2008-09-04;26(11):2955-63.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms.
Authors: Shankar S, Chen Q, Ganapathy S, Singh KP, Srivastava RK
Mol. Cancer Ther., 2008-08-01;7(8):2328-38.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.
Authors: Barbarotto E, Corallini F, Rimondi E, Fadda R, Mischiati C, Grill V, Vaccarezza M, Celeghini C
J. Cell. Biochem., 2008-05-15;104(2):595-605.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
Authors: Toscano F, Fajoui ZE, Gay F, Lalaoui N, Parmentier B, Chayvialle JA, Scoazec JY, Micheau O, Abello J, Saurin JC
Oncogene, 2008-03-17;27(30):4161-71.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
Authors: Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, Dasmahapatra B, Weller M
Cell Death Differ., 2008-01-18;15(4):718-729.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis.
Authors: Locklin RM, Federici E, Espina B, Hulley PA, Russell RG, Edwards CM
Mol. Cancer Ther., 2007-12-07;6(12):3219-28.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells.
Authors: Braun FK, Fecker LF, Schwarz C, Walden P, Assaf C, Durkop H, Sterry W, Eberle J
J. Invest. Dermatol., 2007-05-10;127(10):2425-37.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma.
Authors: Singh TR, Shankar S, Srivastava RK
Oncogene, 2005-07-07;24(29):4609-23.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human TRAILR4/TNFRSF10D Antibody
Average Rating: 4 (Based on 1 Review)
Have you used Human TRAILR4/TNFRSF10D Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
SW480 cells were treated with 5-FU (1 mg/ml) for indicated time points. Total cell lysates were subjected to western blot. PVDF membrane were probed with 1mm/ml Human TRAIL R4 Antibody (MAB633). A specific band was detected for TRAIL R4 at approximately 45-55 kDa. This experiment was conducted under reducing conditions.